Moomoo AI 已提取核心信息
AbbVie Inc., a global biopharmaceutical company, has announced the issuance of $15 billion in senior notes with varying maturities ranging from 2027 to 2064. The offering includes $2.25 billion of 4.800% senior notes due 2027, $2.5 billion of 4.800% senior notes due 2029, $2 billion of 4.950% senior notes due 2031, $3 billion of 5.050% senior notes due 2034, $750 million of 5.350% senior notes due 2044, $3 billion of 5.400% senior notes due 2054, and $1.5 billion of 5.500% senior notes due 2064. Interest on each series of notes is payable semi-annually, commencing September 15, 2024. The company plans to use the net proceeds from the sale of the notes for various corporate purposes, including repaying loans under the New Term Facility, funding the Cerevel merger consideration, repaying outstanding borrowings under the company's commercial paper program, paying related fees and expenses, and for general corporate purposes. The notes were offered through a group of underwriters led by Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, with several other financial institutions participating as joint book-running managers and co-managers. The offering is expected to close on February 26, 2024.
AbbVie Inc., a global biopharmaceutical company, has announced the issuance of $15 billion in senior notes with varying maturities ranging from 2027 to 2064. The offering includes $2.25 billion of 4.800% senior notes due 2027, $2.5 billion of 4.800% senior notes due 2029, $2 billion of 4.950% senior notes due 2031, $3 billion of 5.050% senior notes due 2034, $750 million of 5.350% senior notes due 2044, $3 billion of 5.400% senior notes due 2054, and $1.5 billion of 5.500% senior notes due 2064. Interest on each series of notes is payable semi-annually, commencing September 15, 2024. The company plans to use the net proceeds from the sale of the notes for various corporate purposes, including repaying loans under the New Term Facility, funding the Cerevel merger consideration, repaying outstanding borrowings under the company's commercial paper program, paying related fees and expenses, and for general corporate purposes. The notes were offered through a group of underwriters led by Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, with several other financial institutions participating as joint book-running managers and co-managers. The offering is expected to close on February 26, 2024.
全球生物制药公司艾伯维公司宣布发行150亿美元的优先票据，期限从2027年到2064年不等。此次发行包括2027年到期的22.5亿美元4.800％的优先票据，2029年到期的25亿美元4.800％优先票据，2031年到期的4.950％优先票据，2034年到期的30亿美元5.050％优先票据，2044年到期的7.5亿美元5.400％优先票据，2054年到期的30亿美元5.500％优先票据，以及2064年到期的15亿美元5.500％优先票据。从2024年9月15日起，每系列票据的利息每半年支付一次。该公司计划将出售票据的净收益用于各种公司用途，包括偿还新定期融资机制下的贷款、为Cerevel合并对价提供资金、偿还公司商业票据计划下的未偿借款、支付相关费用和开支以及一般公司用途。这些票据由摩根士丹利、摩根大通、美银证券和花旗集团牵头的一组承销商发行，其他几家金融机构则以联席账面管理人和联席经理的身份参与。此次发行预计将于2024年2月26日结束。
全球生物制药公司艾伯维公司宣布发行150亿美元的优先票据，期限从2027年到2064年不等。此次发行包括2027年到期的22.5亿美元4.800％的优先票据，2029年到期的25亿美元4.800％优先票据，2031年到期的4.950％优先票据，2034年到期的30亿美元5.050％优先票据，2044年到期的7.5亿美元5.400％优先票据，2054年到期的30亿美元5.500％优先票据，以及2064年到期的15亿美元5.500％优先票据。从2024年9月15日起，每系列票据的利息每半年支付一次。该公司计划将出售票据的净收益用于各种公司用途，包括偿还新定期融资机制下的贷款、为Cerevel合并对价提供资金、偿还公司商业票据计划下的未偿借款、支付相关费用和开支以及一般公司用途。这些票据由摩根士丹利、摩根大通、美银证券和花旗集团牵头的一组承销商发行，其他几家金融机构则以联席账面管理人和联席经理的身份参与。此次发行预计将于2024年2月26日结束。
有用
没用
